An international trial published Nov
An international trial published Nov. 7 in the New England Journal of Medicine found that stopping statins in adults 70 and older without cardiovascular disease met a statistical non-inferiority threshold, yet more heart attacks, strokes and deaths occurred in the discontinuation group, according to Mondosanità.
The STREAM trial enrolled 1,880 participants across 24 centers in Switzerland, France and the Netherlands, Mondosanità reported. All were at least 70 years old, with a mean age of 77.5 years and 46.9 percent women. Each had taken a statin for primary prevention — none had a history of heart attack, stroke or documented coronary disease — and each had at least two chronic conditions.
Investigators randomly assigned 938 people to stop the statin and 942 to continue.
The primary outcome was time free of non-fatal myocardial infarction, non-fatal ischemic stroke or death from any cause over two years. The discontinuation group spent a mean of two weeks less event-free than the continuation group (−2.0 weeks). Because the pre-specified non-inferiority margin was 5.2 weeks, the trial formally met its statistical criterion, the study authors wrote. The study was conducted from November 2021 through April 2026.
Despite the statistical finding, raw event numbers diverged. In the discontinuation arm, 119 of 938 participants (12.7 percent) experienced a major event or died. In the continuation arm, 87 of 942 (9.2 percent) did — an absolute difference of 3.5 percentage points, or 32 additional events among those who stopped the drug, Mondosanità reported.
The trial was not powered to test superiority of continuation, but the numerical imbalance indicates a concrete clinical risk, the investigators noted. Researchers collected data on myocardial infarctions, acute ischemic strokes and deaths from any cause during a median follow-up of 103 weeks.
Researchers also measured health-related quality of life, muscle symptoms, falls and sarcopenia. No significant differences emerged between groups, Mondosanità reported. A single patient with documented intolerance may feel better after stopping, but on a population level discontinuation did not produce measurable improvement in daily well-being.
“È necessario un processo decisionale condiviso tra il paziente e l’operatore sanitario per valutare se, nel singolo caso, sia opportuno sospendere il trattamento,” Rodondi added. “In linea generale, tuttavia, per la maggior parte delle persone appartenenti a questa fascia d’età e che non hanno avuto in precedenza eventi cardiovascolari, l’interruzione del farmaco è sicura.”
Previous studies had assessed the safety of stopping statins used for primary prevention in people aged 70 or older and found no differences in mortality, and one study suggested an improvement in quality of life after discontinuation.
The findings apply only to primary prevention. For patients with established cardiovascular disease — secondary prevention — guideline-recommended statin therapy remains a cornerstone and should not be stopped without medical indication, Mondosanità emphasized.
Age alone is an insufficient criterion.
A healthy 72-year-old with elevated LDL cholesterol has a different risk-benefit profile than a frail 90-year-old with limited life expectancy, since preventive benefits accrue over years. Shared decision-making should weigh LDL levels, comorbidities, frailty and patient preferences, the report concluded.